Browsing NTNU Open by Author "Halvorsen, Tarje Onsøien"
Now showing items 1-20 of 26
-
A study of Glasgow Prognostic Score (GPS) and change in Health-Related Quality of Life (HRQoL) in advanced non-small cell lung cancer (NSCLC)
Oliversen, Ole Aleksander Skaug (Master thesis, 2022)Sammendrag Bakgrunn Lungekreft er en dødelig sykdom assosiert med høy grad av systemisk inflammasjon. Glasgow Prognostic Score (GPS) er basert på albumin og C-reaktivt protein (CRP). GPS er en prognostisk faktor for ... -
Associations between detectable circulating tumor DNA and tumor glucose uptake measured by 18F-FDG PET/CT in early-stage non-small cell lung cancer
Ottestad, Anine Larsen; Johansen, Håkon; Halvorsen, Tarje Onsøien; Dai, Hong Yan; Wahl, Sissel Gyrid Freim; Emdal, Elisabeth Fritzke; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2023)Background The low level of circulating tumor DNA (ctDNA) in the blood is a well-known challenge for the application of liquid biopsies in early-stage non-small cell lung cancer (NSCLC) management. Studies of metastatic ... -
Associations between Measured and Patient-Reported Physical Function and Survival in Advanced NSCLC
Stokke, Kristin; Halvorsen, Tarje Onsøien; Grønberg, Bjørn Henning; Saltvedt, Ingvild; Jordhøy, Marit Slaaen; Kirkevold, Øyvind; Killingberg, Kristin Toftaker; Sandvei, Marie Søfteland (Peer reviewed; Journal article, 2022)Background: There is a lack of tools for selecting patients with advanced lung cancer who benefit the most from systemic treatment. Patient-reported physical function (PRPF) has been identified as a prognostic factor in ... -
Associations between muscle measures, survival and toxicity in patients with limited disease small cell lung cancer receiving concurrent chemoradiotherapy
Halvorsen, Tarje Onsøien; Valan, Christine Damgaard; Jordhøy, Marit Slaaen; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2020)Background Standard treatment for patients with limited stage small cell lung cancer (LS SCLC) is concurrent platinum– etoposide chemotherapy and thoracic radiotherapy (TRT). Up to 30% of patients are cured, but severe ... -
Associations between severe co-morbidity and muscle measures in advanced non-small cell lung cancer patients
Grønberg, Bjørn Henning; Valan, Christine Damgaard; Halvorsen, Tarje Onsøien; Sjøblom, Bjørg; Jordhøy, Marit Slaaen (Journal article; Peer reviewed, 2019)Introduction Several studies show that low skeletal muscle index (SMI) and low skeletal muscle density (SMD) are negative prognostic factors and associated with more toxicity from systemic therapy in cancer patients. ... -
Associations between tumor mutations in cfDNA and survival in non-small cell lung cancer
Ottestad, Anine Larsen; Hong, Yan Dai; Halvorsen, Tarje Onsøien; Emdal, Elisabeth Fritzke; Wahl, Sissel Gyrid Freim; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2021)Introduction: Studies have indicated that detection of mutated KRAS or EGFR in circulating tumor DNA (ctDNA) from pre-treatment plasma samples is a negative prognostic factor for non-small cell lung cancer (NSCLC) pa-tients. ... -
Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT-1 trial
Horndalsveen, Henrik; Alver, Tine Norman; Dalsgaard, Astrid Marie; ROGG, LOTTE VICTORIA; Helbekkmo, Nina; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Ramberg, Christina; Haakensen, Vilde Drageset; Øjlert, Åsa Kristina; Bjaanæs, Maria Moksnes; Helland, Åslaug (Peer reviewed; Journal article, 2022)The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non-small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical ... -
Changes in muscle measures during chemoradiotherapy in patients with limited stage small cell lung cancer
Valan, Christine Damgaard; Halvorsen, Tarje Onsøien; Jordhøy, Marit Slaaen; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2020)Background: Concurrent chemoradiotherapy is the recommended treatment for limited stage small cell lung cancer. Severe side‐effects, which might cause loss of muscle mass, are frequent. Low skeletal muscle index (SMI) and ... -
Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer
Halvorsen, Tarje Onsøien; Sundstrøm, Stein Harald; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Kaasa, Stein; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2016)Background: Many patients with limited disease small cell lung cancer (LD SCLC) suffer from comorbidity. Not all patients with comorbidity are offered standard treatment, though there is little evidence for such a policy. ... -
Development of EirV3 - a computer-based tool for patient reported outcome measures in cancer
Krogstad, Hilde; Brunelli, Cinzia; Sand, Kari; Andersen, Eivind; Garresori, Herish; Halvorsen, Tarje Onsøien; Haukland, Ellinor Christin; Jordal, Frode; Kaasa, Stein; Loge, Jon Håvard; Løhre, Erik Torbjørn; Raj, Sunil Xavier; Hjermstad, Marianne Jensen (Journal article; Peer reviewed, 2017)Purpose Immediate transfer of patient-reported outcome measures (PROMs) for use in medical consultations is facilitated by electronic assessments. We aimed to describe the rationale and development of Eir version 3 (EirV3), ... -
Fragmentation assessment of FFPE DNA helps in evaluating NGS library complexity and interpretation of NGS results
Ottestad, Anine Larsen; Emdal, Elisabeth Fritzke; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Dai, Hong Yan (Journal article; Peer reviewed, 2022) -
Maintenance pemetrexed therapy in advanced non-smallcell lung cancer
Stokke, Kristin (Doctoral theses at NTNU;2023:312, Doctoral thesis, 2023)Lung cancer is the most common cancer world-wide, the third most common in Norway after colonand breast cancer, but the most common cause of cancer-related deaths both globally and nationally (1, 2). In 2021, 3499 new cases ... -
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer
Killingberg, Kristin Toftaker; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; HORNSLIEN, KJERSTI; Madebo, Tesfaye; Langer, Seppo W.; Schytte, Tine; Risum, Signe; Tsakonas, Georgios; Nyman, Jan; Engleson, Jens; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2022)Objectives In a randomized phase II trial, twice daily (BID) thoracic radiotherapy (TRT) of 60 Gy/40 fractions improved survival compared with 45 Gy/30 fractions in limited stage small-cell lung cancer (LS SCLC). Notably, ... -
Prognostic and predictive factors in limited disease small-cell lung cancer
Valan, Christine Damgaard (Doctoral theses at NTNU;2020:203, Doctoral thesis, 2020)Lung cancer is the most common type of cancer and the leading cause of cancer related deaths. Small cell lung cancer (SCLC) is one of two main types of lung cancer. Concurrent chemoradiotherapy is recommended for SCLC if ... -
The prognostic effect of KRAS mutations in non-small cell lung carcinoma revisited: A norwegian multicentre study
Wahl, Sissel Gyrid Freim; Hong, Yan Dai; Emdal, Elisabeth Fritzke; Berg, Thomas; Halvorsen, Tarje Onsøien; Ottestad, Anine Larsen; Lund-Iversen, Marius; Brustugun, Odd; Førde, Dagny; Paulsen, Erna-Elise; Donnem, Tom; Andersen, Sigve; Grønberg, Bjørn Henning; Richardsen, Elin (Peer reviewed; Journal article, 2021)Background: due to emerging therapeutics targeting KRAS G12C and previous reports with conflicting results regarding the prognostic impact of KRAS and KRAS G12C in non-small cell lung cancer (NSCLC), we aimed to investigate ... -
Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy
Wahl, Sissel Gyrid Freim; Hong, Yan Dai; Emdal, Elisabeth Fritzke; Ottestad, Anine Larsen; Dale, Vibeke Grotnes; Richardsen, Elin; Halvorsen, Tarje Onsøien; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2021)Droplet digital polymerase chain reaction (ddPCR) is a highly sensitive and accurate method for quantication of nucleic acid sequences. We used absolute quantication of mutated v-Ki-ras2 Kirsten rat sarcoma viral oncogene ... -
Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer
Stokke, Kristin; Sandvei, Marie Søfteland; Grønberg, Bjørn Henning; Jordhøy, Marit Slaaen; Killingberg, Kristin Toftaker; Halvorsen, Tarje Onsøien (Peer reviewed; Journal article, 2022)Background: The Glasgow prognostic score (GPS) is an established inflammatory prognostic index in cancer patients. Most studies have only measured GPS at baseline (B-GPS). Effective cancer therapy may reduce inflammation, ... -
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer
Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Tollåli, Terje; Hornslien, Kjersti; Aksnessæther, Bjørg Y.; Liaaen, Erik Dyb; Sundstrøm, Stein Harald (Journal article; Peer reviewed, 2016)Background: Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small cell lung cancer (LD SCLC). Twice daily TRT is well documented, but not universally implemented – probably mainly ... -
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
Halvorsen, Tarje Onsøien; Stokke, Kristin; Killingberg, Kristin Toftaker; Raj, Sunil Xavier; Sørhaug, Sveinung; Brustugun, Odd Terje; Fløtten, Øystein; Helbekkmo, Nina; Hornslien, Kjersti; Madebo, Tesfaye; Fluge, Sverre; Grønberg, Bjørn Henning (Peer reviewed; Journal article, 2020)Objectives: Two phase III trials show that maintenance pemetrexed therapy after platinum-doublet chemotherapy prolongs overall survival (OS) and progression free survival (PFS) in advanced non-squamous non-small-cell lung ... -
Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement
Valan, Christine Damgaard; Slagsvold, Jens Erik; Halvorsen, Tarje Onsøien; Herje, Martin; Bremnes, Roy M.; Brunsvig, Paal Fr.; Brustugun, Odd Terje; Fløtten, Øystein; Levin, Nina; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Peer reviewed, 2018)Background/Aim: There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules ...